|
| 37767674 | Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial. | JACC Heart Fail | 2024 |
| 37713477 | Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. | Diabetes Care | 2024 |
| 37952176 | Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. | JAMA Cardiol | 2024 |
| 36342789 | Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. | Circulation | 2023 |
| 37634707 | Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. | J Am Coll Cardiol | 2023 |
| 37632711 | Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37632463 | Ferric Carboxymaltose in Heart Failure with Iron Deficiency. | N Engl J Med | 2023 |
| 37632455 | Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. | Circulation | 2023 |
| 37632415 | Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. | Eur Heart J | 2023 |
| 37622416 | Baseline characteristics of patients enrolled in the EMPACT-MI trial. | Eur J Heart Fail | 2023 |
| 37481202 | "Click and mortar" opportunities for digitization and consumerism in trials. | Contemp Clin Trials | 2023 |
| 37792369 | Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. | JAMA Cardiol | 2023 |
| 37479054 | Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials. | J Card Fail | 2023 |
| 37886880 | Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. | Circ Heart Fail | 2023 |
| 37610398 | Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37830208 | Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. | Circulation | 2023 |
| 37771274 | Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37671551 | Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial. | Circulation | 2023 |
| 37598795 | Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial. | Am Heart J | 2023 |
| 37532422 | GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes. | J Am Coll Cardiol | 2023 |
| 37220822 | Operational challenges and mitigation measures during the COVID-19 pandemic-Lessons from DELIVER. | Am Heart J | 2023 |
| 37025023 | Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study. | Vasc Med | 2023 |
| 37290700 | Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. | Am Heart J | 2023 |
| 37220172 | Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. | Eur Heart J | 2023 |
| 37220093 | Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. | Eur Heart J | 2023 |
| 37318420 | Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction. | JACC Heart Fail | 2023 |
| 37417824 | Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial. | Circ Heart Fail | 2023 |
| 37449573 | Splanchnic Nerve Modulation Effects on Surrogate Measures of Venous Capacitance. | J Am Heart Assoc | 2023 |
| 37212758 | Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. | J Am Coll Cardiol | 2023 |
| 37212168 | Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial. | Eur J Heart Fail | 2023 |
| 37211977 | Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. | Eur J Heart Fail | 2023 |
| 37210743 | Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. | Eur Heart J | 2023 |
| 37210608 | Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF. | Eur J Heart Fail | 2023 |
| 37208998 | Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. | JAMA Cardiol | 2023 |
| 37338878 | Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke. | JAMA | 2023 |
| 37137660 | Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. | JACC Heart Fail | 2023 |
| 37435958 | Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank. | Clin Infect Dis | 2023 |
| 37099283 | Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. | JAMA Cardiol | 2023 |
| 37331690 | Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial. | J Card Fail | 2023 |
| 37294244 | Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. | JACC Heart Fail | 2023 |
| 37226448 | Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. | JACC Heart Fail | 2023 |
| 37328184 | Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. | BMJ Open | 2023 |
| 37293003 | Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy. | medRxiv | 2023 |
| 36924335 | Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure - mechanism of action (SPONGE-HF). | Eur J Heart Fail | 2023 |
| 36653095 | Albuminuria and Heart Failure: JACC State-of-the-Art Review. | J Am Coll Cardiol | 2023 |
| 36445019 | Utilization and Outcomes of Extracorporeal Membrane Oxygenation Following Traumatic Brain Injury in the United States. | J Intensive Care Med | 2023 |
| 36881399 | Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. | JACC Heart Fail | 2023 |
| 36881395 | Medication-Attributable Adverse Events in Heart Failure Trials. | JACC Heart Fail | 2023 |
| 36811901 | Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. | JAMA Cardiol | 2023 |
| 36876483 | Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. | Circulation | 2023 |